Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
Key facts
- Where
- San Francisco, United StatesSee the 3 sites
Where in United States
- Satellite Healthcare - Daly CitySan Francisco, United StatesTaking people
- Satellite Healthcare - San Francisco GearySan Francisco, United StatesTaking people
- Zuckerberg San Francisco General HospitalSan Francisco, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT07910773
- Record updated
- 6 November 2026
- Original description
The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study.Read full original descriptionShow less
The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study.
Researchers will compare two goals for the top blood pressure number (systolic blood pressure): below 120 mmHg versus below 140 mmHg.This pilot study will help plan a larger trial in the future.
Participants will:
* Be assigned by chance to one of the two blood pressure goals. * Have their blood pressure measured at clinic visits about every two weeks. * Work with their kidney doctor on recommended changes to fluid management, peritoneal dialysis treatment, or blood pressure medicines to reach their assigned goal. * Be part of the study for about four and a half months.
Inclusion: Age ≥ 18 years; Undergoing regular PD for treatment of ESKD; On PD for ≥ 4 months. (We do not plan to enroll patients within the first 3 months of PD initiation because there can be large fluctuations in volume status and BP readings before patient coming into more of a steady state. We then require participants to have at least 1 month of BP data to allow calculation of an average pre-enrollment BP for screening for study entry.); Diagnosis of HTN defined as being on antihypertensive medications or having routine clinic SBP ≥ 140 mmHg averaged over prior one month to screening; Able to measure brachial BP.
Exclusion: Planned transplant or HD transition < 4.5 months (the duration of study); Pregnancy, anticipated pregnancy, or breastfeeding as this will limit the use of certain antihypertension medications in the study and pose additional risks to the patient and many pregnant patients are transitioned over to hemodialysis; Presence of a condition or abnormality that, in the opinion of the study team or treating nephrologist, would compromise the safety of the patient or the quality of the data; Estimated life expectancy < 4.5 months (also determined by asking the treating nephrologist); Participation in another clinical trial that may affect BP management; Incarceration or institutionalized living which may prohibit measurement of home BP.